KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $10.6 billion.

  • Bio-Rad Laboratories' Liabilities and Shareholders Equity rose 1294.73% to $10.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $40.0 billion, marking a year-over-year increase of 26876.79%. This contributed to the annual value of $10.6 billion for FY2025, which is 1294.73% up from last year.
  • Latest data reveals that Bio-Rad Laboratories reported Liabilities and Shareholders Equity of $10.6 billion as of Q4 2025, which was up 1294.73% from $9.7 billion recorded in Q3 2025.
  • Bio-Rad Laboratories' Liabilities and Shareholders Equity's 5-year high stood at $20.0 billion during Q3 2021, with a 5-year trough of $363.5 million in Q4 2021.
  • Over the past 5 years, Bio-Rad Laboratories' median Liabilities and Shareholders Equity value was $10.4 billion (recorded in 2025), while the average stood at $8.9 billion.
  • In the last 5 years, Bio-Rad Laboratories' Liabilities and Shareholders Equity tumbled by 9640.24% in 2024 and then soared by 196345.45% in 2025.
  • Over the past 5 years, Bio-Rad Laboratories' Liabilities and Shareholders Equity (Quarter) stood at $363.5 million in 2021, then grew by 23.47% to $448.8 million in 2022, then increased by 9.87% to $493.1 million in 2023, then skyrocketed by 1799.03% to $9.4 billion in 2024, then grew by 12.95% to $10.6 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $10.6 billion for Q4 2025, versus $9.7 billion for Q3 2025 and $10.2 billion for Q2 2025.